Liver cancer, specifically hepatocellular carcinoma (HCC), represents one of the largest and most established application areas for tumor ablation globally. Given the high incidence of HCC worldwide and the frequency with which patients present with tumors unsuitable for surgical removal, ablation techniques have become an indispensable first-line therapy for early-stage liver tumors. The liver’s unique anatomy and high blood flow, while presenting technical challenges, also make it an ideal target for thermal modalities due to the localized effect of the energy.

The dominance of the Liver Cancer Ablation Procedures segment in the overall market revenue—accounting for approximately 35% of the total market share in 2024—is a testament to the clinical utility of RFA and MWA in this setting. Both radiofrequency and microwave platforms have seen continuous improvements, focusing on optimizing energy delivery to ensure complete tumor destruction, especially near major vascular structures where the 'heat sink' effect must be overcome. The goal is to achieve local cure rates comparable to surgical resection for small tumors, without the associated morbidity.

Technological advancements are now allowing for the use of ablation in increasingly complex cases, including bridging therapy for patients awaiting liver transplantation or for tumors up to 5 cm in size. The integration of advanced fusion imaging, combining live ultrasound with pre-procedural CT or MRI scans, has dramatically enhanced the accuracy and safety of needle placement, ensuring more complete coverage of the tumor margins and reducing recurrence risk. This precision is vital for the long-term success of the treatment.

The rising global burden of chronic liver disease, driven by viral hepatitis and non-alcoholic fatty liver disease, suggests that the volume of liver cancer cases amenable to ablation will continue to increase. Consequently, R&D efforts are focused on non-thermal approaches, such as Irreversible Electroporation (IRE), which spares major vessels and bile ducts, offering a crucial alternative for challenging perivascular tumors. This commitment to therapeutic diversification will ensure the liver cancer application segment remains the primary revenue driver for the foreseeable future.